Nature Communications (Sep 2016)
Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration
- Marcel Smid,
- F. Germán Rodríguez-González,
- Anieta M. Sieuwerts,
- Roberto Salgado,
- Wendy J. C. Prager-Van der Smissen,
- Michelle van der Vlugt-Daane,
- Anne van Galen,
- Serena Nik-Zainal,
- Johan Staaf,
- Arie B. Brinkman,
- Marc J. van de Vijver,
- Andrea L. Richardson,
- Aquila Fatima,
- Kim Berentsen,
- Adam Butler,
- Sancha Martin,
- Helen R. Davies,
- Reno Debets,
- Marion E. Meijer-Van Gelder,
- Carolien H. M. van Deurzen,
- Gaëtan MacGrogan,
- Gert G. G. M. Van den Eynden,
- Colin Purdie,
- Alastair M. Thompson,
- Carlos Caldas,
- Paul N. Span,
- Peter T. Simpson,
- Sunil R. Lakhani,
- Steven Van Laere,
- Christine Desmedt,
- Markus Ringnér,
- Stefania Tommasi,
- Jorunn Eyford,
- Annegien Broeks,
- Anne Vincent-Salomon,
- P. Andrew Futreal,
- Stian Knappskog,
- Tari King,
- Gilles Thomas,
- Alain Viari,
- Anita Langerød,
- Anne-Lise Børresen-Dale,
- Ewan Birney,
- Hendrik G. Stunnenberg,
- Mike Stratton,
- John A. Foekens,
- John W. M. Martens
Affiliations
- Marcel Smid
- Department of Medical Oncology, Erasmus MC Cancer Institute and Cancer Genomics Netherlands, Erasmus University Medical Center
- F. Germán Rodríguez-González
- Department of Medical Oncology, Erasmus MC Cancer Institute and Cancer Genomics Netherlands, Erasmus University Medical Center
- Anieta M. Sieuwerts
- Department of Medical Oncology, Erasmus MC Cancer Institute and Cancer Genomics Netherlands, Erasmus University Medical Center
- Roberto Salgado
- Breast Cancer Translational Research Laboratory, Université Libre de Bruxelles
- Wendy J. C. Prager-Van der Smissen
- Department of Medical Oncology, Erasmus MC Cancer Institute and Cancer Genomics Netherlands, Erasmus University Medical Center
- Michelle van der Vlugt-Daane
- Department of Medical Oncology, Erasmus MC Cancer Institute and Cancer Genomics Netherlands, Erasmus University Medical Center
- Anne van Galen
- Department of Medical Oncology, Erasmus MC Cancer Institute and Cancer Genomics Netherlands, Erasmus University Medical Center
- Serena Nik-Zainal
- Wellcome Trust Sanger Institute
- Johan Staaf
- Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University
- Arie B. Brinkman
- Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen
- Marc J. van de Vijver
- Department of Pathology, Academic Medical Center
- Andrea L. Richardson
- Department of Pathology, Brigham and Women's Hospital
- Aquila Fatima
- Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center
- Kim Berentsen
- Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen
- Adam Butler
- Wellcome Trust Sanger Institute
- Sancha Martin
- Wellcome Trust Sanger Institute
- Helen R. Davies
- Wellcome Trust Sanger Institute
- Reno Debets
- Department of Medical Oncology, Erasmus MC Cancer Institute and Cancer Genomics Netherlands, Erasmus University Medical Center
- Marion E. Meijer-Van Gelder
- Department of Medical Oncology, Erasmus MC Cancer Institute and Cancer Genomics Netherlands, Erasmus University Medical Center
- Carolien H. M. van Deurzen
- Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center
- Gaëtan MacGrogan
- Département de Biopathologie,
- Gert G. G. M. Van den Eynden
- Department of Pathology/TCRU GZA
- Colin Purdie
- Department of Pathology, Ninewells Hospital & Medical School
- Alastair M. Thompson
- Department of Pathology, Ninewells Hospital & Medical School
- Carlos Caldas
- Cancer Research UK Cambridge Institute, University of Cambridge
- Paul N. Span
- Department of Radiation Oncology, Radboud University Medical Center
- Peter T. Simpson
- The University of Queensland: UQ Centre for Clinical Research and School of Medicine
- Sunil R. Lakhani
- The University of Queensland: UQ Centre for Clinical Research and School of Medicine
- Steven Van Laere
- Center for Oncological Research, University of Antwerp & GZA Hospitals Sint-Augustinus
- Christine Desmedt
- Breast Cancer Translational Research Laboratory, Université Libre de Bruxelles
- Markus Ringnér
- Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University
- Stefania Tommasi
- IRCCS Istituto Tumori ‘Giovanni Paolo II’
- Jorunn Eyford
- Cancer Research Laboratory, Faculty of Medicine, University of Iceland
- Annegien Broeks
- The Netherlands Cancer Institute
- Anne Vincent-Salomon
- Department of Pathology and INSERM U934, Institut Curie
- P. Andrew Futreal
- Department of Genomic Medicine, UT MD Anderson Cancer Center
- Stian Knappskog
- Department of Clinical Science, University of Bergen
- Tari King
- Memorial Sloan Kettering Cancer Center
- Gilles Thomas
- Synergie Lyon Cancer,Centre Léon Bérard
- Alain Viari
- Synergie Lyon Cancer,Centre Léon Bérard
- Anita Langerød
- Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital The Norwegian Radiumhospital
- Anne-Lise Børresen-Dale
- Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital The Norwegian Radiumhospital
- Ewan Birney
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Trust Genome Campus
- Hendrik G. Stunnenberg
- Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen
- Mike Stratton
- Wellcome Trust Sanger Institute
- John A. Foekens
- Department of Medical Oncology, Erasmus MC Cancer Institute and Cancer Genomics Netherlands, Erasmus University Medical Center
- John W. M. Martens
- Department of Medical Oncology, Erasmus MC Cancer Institute and Cancer Genomics Netherlands, Erasmus University Medical Center
- DOI
- https://doi.org/10.1038/ncomms12910
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 9
Abstract
Recent studies using in depth DNA sequencing techniques led to the identification of cancer driver genes but mainly focused on the effect on their expression. Here, the authors analyse 266 cases of breast cancer and report gene expression signatures associated with the number and character of signature mutations.
